Facet Biotech
NEW YORK — Drug and medical products company Abbott Laboratories said Tuesday it will buy Facet Biotech Corp. for about $450 million in cash, expanding the company’s access to biotechnology drugs, including a potential treatment for multiple sclerosis.
Facet and its partner Biogen Idec plan to move the potential multiple sclerosis drug daclizumab into late-stage development in the second quarter. Facet also has potential cancer treatments in various stages of development with other partners.
Loading
Related Youtube Video on ""
Video Loading...
Search more : Drug and Medical – Abbott paying $450 million for Facet Biotech
Advertisement
Related Twitter on "" Related Digg.com ""
Related Stories on Digg
See more popular stories on Digg.com
See more stories dugg by tagecho on Digg.com
Related Post""
Processing your request, Please wait....
